98%
921
2 minutes
20
Paradoxical reactions to tuberculosis (TB) treatment are characterized by an initial improvement of the clinical symptoms followed by clinical or radiological deterioration of existing tuberculous lesions, or by development of new lesions. Intestinal perforation in gastrointestinal TB can occur as a paradoxical reaction to antitubercular therapy. A 55-year-old man visited the outpatient department with lower abdominal pain and weight loss. He was diagnosed with intestinal TB and started antitubercular therapy. After 3 months of antitubercular therapy, a colonoscopy revealed improvement of the disease. Three days after the colonoscopy, the patient visited the emergency room complaining of abdominal pain. Abdominal computed tomography revealed extraluminal air-filled spaces in the pelvic cavity. We diagnosed a small bowel perforation and performed an emergency laparotomy and a right hemicolectomy with small bowel resection. This report describes the case of intestinal perforation presenting as a paradoxical reaction to antitubercular and provides a brief literature review.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8359699 | PMC |
http://dx.doi.org/10.3393/ac.2020.03.16.1 | DOI Listing |
BMJ Case Rep
September 2025
Cardiology, Dr D Y Patil Medical College Hospital and Research Centre, Pune, Maharashtra, India
Constrictive pericarditis is a condition in which inflammation of the pericardium results in the loss of pericardial elasticity, leading to restricted ventricular filling. This case reports a male in his 50s who presented with symptoms of bilateral pedal oedema and dyspnoea. Examination revealed a raised jugular venous pulse, abdominal dullness and crepitations in both lungs.
View Article and Find Full Text PDFPLoS Negl Trop Dis
September 2025
Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Background: The Maltalep trial in Bangladesh assessed whether single-dose rifampicin (SDR) given 8-12 weeks after bacillus Calmette-Guérin (BCG) vaccination was able to prevent excess leprosy cases due to BCG in contacts of newly diagnosed leprosy patients. After previous publication of the two years follow-up results of the trial, we now review the results after five years. Furthermore, to better understand the long-term protective effects of BCG against leprosy, we conduct post-hoc in-depth secondary statistical analyses based on the prospective interventional (randomized) Maltalep trial and a non-interventional (non-randomized) cohort study that was conducted simultaneously in the same project area.
View Article and Find Full Text PDFACS Appl Mater Interfaces
September 2025
School of Pharmacy, Queen's University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast BT9 7BL, U.K.
Tuberculosis (TB), caused by , remains a global health emergency, particularly in low- and middle-income countries. Despite effective pharmacotherapy, prolonged treatment, poor adherence, and drug resistance continue to hinder eradication. Isoniazid (ISZ), a first-line antitubercular drug, is effective but limited by high aqueous solubility and short half-life, necessitating daily administration and causing plasma fluctuations.
View Article and Find Full Text PDFBMJ Open Respir Res
September 2025
World Health Organization Regional Office for Europe, Copenhagen, Denmark.
Introduction: Despite WHO's recommendations and the 2023-2030 Tuberculosis (TB) action plan, uptake of TB preventive treatment (TPT) remains suboptimal. In this paper, we use two countries of the WHO Europe Region, the Republic of Moldova and Georgia, that are at different stages of implementation of TB prevention policies, as a case study to examine health system barriers and facilitators to TPT scale-up.
Methods: In this case study, we used methods of qualitative research-interviews with three stakeholder groups: health service providers and National TB Programme staff; civil society organisations and international partners or donors.
Ther Drug Monit
September 2025
Laboratory of Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Turin, Amedeo di Savoia Hospital, Turin, Italy; and.
Background: Tuberculosis (TB) treatment relies on a prolonged first-line antibiotic regimen, including isoniazid, rifampicin (RF), ethambutol (EMB), and pyrazinamide.Pharmacogenetics plays a crucial role in optimizing TB treatment by addressing individual variability in drug metabolism and responses. Genetic polymorphisms can significantly affect pharmacokinetics and therapeutic outcomes.
View Article and Find Full Text PDF